Iterum Therapeutics (ITRM) to Release Quarterly Earnings on Wednesday

Iterum Therapeutics (NASDAQ:ITRM) is expected to be releasing its Q1 2026 results before the market opens on Wednesday, May 20th. Analysts expect Iterum Therapeutics to post earnings of ($0.10) per share and revenue of $1.40 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Monday, May 18, 2026 at 12:30 PM ET.

Iterum Therapeutics Stock Performance

NASDAQ:ITRM opened at $0.03 on Wednesday. Iterum Therapeutics has a 1 year low of $0.03 and a 1 year high of $1.42. The firm’s fifty day simple moving average is $0.09 and its 200 day simple moving average is $0.29. The firm has a market capitalization of $1.60 million, a PE ratio of -0.04 and a beta of 2.96.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on ITRM. HC Wainwright lowered shares of Iterum Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, March 30th. Maxim Group lowered shares of Iterum Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, March 4th. Two research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Reduce”.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Virtu Financial LLC acquired a new position in shares of Iterum Therapeutics during the third quarter valued at about $32,000. Jane Street Group LLC acquired a new position in shares of Iterum Therapeutics during the second quarter valued at about $92,000. Finally, Alchemi Wealth LLC acquired a new position in shares of Iterum Therapeutics during the fourth quarter valued at about $90,000. Institutional investors and hedge funds own 9.21% of the company’s stock.

Iterum Therapeutics Company Profile

Iterum Therapeutics plc is a clinical-stage biopharmaceutical company focused on the development and commercialization of anti-infective products targeting drug-resistant bacterial infections. The company’s research efforts are centered on novel therapeutic agents designed to address serious community-acquired and hospital-acquired infections where current treatment options are limited by emerging resistance.

The company’s lead product candidate, sulopenem, is being evaluated in both intravenous and oral formulations for the treatment of complicated urinary tract infections (cUTI) and intra-abdominal infections (IAI).